Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free NAGE Stock Alerts

Niagen Bioscience (NAGE) Financials

Niagen Bioscience logo
$2.58 +0.06 (+2.17%)
As of 10:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Niagen Bioscience

Annual Income Statements for Niagen Bioscience

This table shows Niagen Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/2/2016 12/31/2016 12/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.77 -2.93 -11 -33 -32 -20 -27 -17 -4.94 8.55 17
Consolidated Net Income / (Loss)		 -2.77 -2.93 -11 -33 -32 -20 -27 -17 -4.94 8.55 17
Net Income / (Loss) Continuing Operations		 -2.64 -3.55 -17 -33 -32 -20 -27 -17 -4.94 8.55 17
Total Pre-Tax Income 		-2.63 -3.55 -17 -33 -32 -20 -27 -19 -4.94 8.86 18
Total Operating Income		 -2.07 -2.91 -16 -33 -31 -20 -27 -19 -5.60 7.73 16
Total Gross Profit		 7.53 10 10 16 26 35 41 43 51 62 83
Total Revenue		 18 22 21 32 46 59 67 72 84 100 129
Operating Revenue		 18 22 21 32 46 59 67 72 84 100 129
Total Cost of Revenue		 10 11 11 16 21 24 26 29 33 38 46
Operating Cost of Revenue		 10 11 11 16 21 24 26 29 33 38 46
Total Operating Expenses		 9.60 13 27 49 57 55 69 61 56 54 67
Selling, General & Admin Expense		 7.20 9.21 18 27 34 31 36 28 25 18 27
Marketing Expense		 1.51 1.56 4.46 17 18 21 28 28 26 29 36
Research & Development Expense		 0.89 2.52 4.01 5.48 4.42 3.42 3.83 4.83 4.96 6.02 6.33
Other Operating Expenses / (Income)		 - - - - - - - - - 0.00 -1.98
Total Other Income / (Expense), net		 -0.57 -0.65 -0.15 -0.14 -0.85 -0.07 -0.06 0.00 0.66 1.13 1.91
Interest & Investment Income		 - - - - - - - - 0.66 1.13 2.13
Other Income / (Expense), net		 0.00 0.00 - -0.07 -0.85 - - - - 0.00 -0.21
Income Tax Expense		 -0.00 0.00 - - - - - - 0.00 0.31 0.81
Basic Earnings per Share		 ($0.08) ($0.08) ($0.26) ($0.61) ($0.56) ($0.33) ($0.40) ($0.24) ($0.07) $0.11 $0.22
Weighted Average Basic Shares Outstanding		 35.88M 37.29M 44.60M 55.01M 57.06M 61.07M 67.19M 69.73M 74.99M 75.93M 79.18M
Diluted Earnings per Share		 ($0.08) ($0.08) ($0.26) ($0.61) ($0.56) ($0.33) ($0.40) ($0.24) ($0.07) $0.11 $0.20
Weighted Average Diluted Shares Outstanding		 35.88M 37.29M 44.60M 55.01M 57.06M 61.07M 67.19M 69.73M 74.99M 78.13M 85.44M
Weighted Average Basic & Diluted Shares Outstanding		 35.88M 37.29M 44.60M 55.01M 57.06M 61.07M 68.31M 74.84M 75.31M 77.75M 80.08M

Quarterly Income Statements for Niagen Bioscience

This table shows Niagen Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 0.11 -0.49 -0.02 1.88 7.18 5.06 3.61 4.58 4.13 6.32 0.96
Consolidated Net Income / (Loss)		 0.11 -0.49 -0.02 1.88 7.18 5.06 3.61 4.58 4.13 6.32 0.96
Net Income / (Loss) Continuing Operations		 0.11 -0.49 -0.02 1.88 7.18 5.06 3.61 4.58 4.13 6.32 0.96
Total Pre-Tax Income 		0.11 -0.49 -0.02 1.88 7.48 5.23 3.74 4.80 4.42 6.74 1.07
Total Operating Income		 -0.17 -0.73 -0.26 1.60 7.11 4.77 3.19 4.24 4.09 1.58 0.70
Total Gross Profit		 13 13 14 16 18 19 20 22 22 20 19
Total Revenue		 21 22 23 26 29 30 31 34 34 31 30
Operating Revenue		 21 22 23 26 29 30 31 34 34 31 30
Total Cost of Revenue		 8.26 8.70 9.05 9.34 11 11 11 12 12 11 10
Operating Cost of Revenue		 8.26 8.70 9.05 9.34 11 11 11 12 12 11 10
Total Operating Expenses		 13 14 14 15 11 15 17 18 18 18 19
Selling, General & Admin Expense		 5.43 5.35 5.66 6.30 1.06 5.18 7.27 7.13 7.48 7.24 6.97
Marketing Expense		 6.52 6.74 6.97 7.04 8.72 8.12 8.21 8.77 10 9.68 10
Research & Development Expense		 1.16 2.10 1.32 1.29 1.32 1.26 1.57 1.80 1.71 1.48 1.51
Total Other Income / (Expense), net		 0.28 0.24 0.24 0.28 0.37 0.46 0.55 0.56 0.34 5.16 0.37
Interest & Investment Income		 - 0.24 0.24 0.28 - 0.46 0.55 0.56 0.55 0.38 0.37
Other Income / (Expense), net		 - - - - - 0.00 0.00 - - 4.78 -0.00
Income Tax Expense		 - 0.00 0.00 0.00 - 0.17 0.13 0.22 0.29 0.42 0.11
Basic Earnings per Share		 - ($0.01) $0.00 $0.02 $0.10 $0.07 $0.05 $0.06 $0.04 $0.08 $0.01
Weighted Average Basic Shares Outstanding		 74.99M 75.23M 75.56M 75.97M 75.93M 77.81M 79.25M 79.78M 79.18M 79.92M 79.32M
Diluted Earnings per Share		 - ($0.01) $0.00 $0.02 $0.10 $0.06 $0.04 $0.05 $0.05 $0.07 $0.01
Weighted Average Diluted Shares Outstanding		 74.99M 75.23M 75.56M 77.77M 78.13M 83.23M 86.24M 86.62M 85.44M 84.57M 82.50M
Weighted Average Basic & Diluted Shares Outstanding		 75.31M 75.54M 75.93M 76.38M 77.75M 78.77M 79.75M 79.81M 80.08M 79.64M 79.13M

Annual Cash Flow Statements for Niagen Bioscience

This table details how cash moves in and out of Niagen Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/2/2016 12/31/2016 12/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.58 -3.91 44 -23 -3.80 -2.12 12 -7.78 6.88 17 20
Net Cash From Operating Activities		 -2.11 -2.94 -9.80 -21 -20 -11 -24 -15 7.12 12 14
Net Cash From Continuing Operating Activities		 8.68 5.08 -4.51 -18 -12 -11 -24 -15 7.12 12 14
Net Income / (Loss) Continuing Operations		 -2.77 -2.93 -11 -33 -32 -20 -27 -17 -4.94 8.55 17
Consolidated Net Income / (Loss)		 -2.77 -2.93 -11 -33 -32 -20 -27 -17 -4.94 8.55 17
Depreciation Expense		 0.29 0.33 0.51 0.61 0.76 0.87 0.89 0.87 0.87 0.66 0.61
Amortization Expense		 0.05 0.09 0.21 0.24 1.61 0.64 0.74 1.02 0.16 0.15 0.17
Non-Cash Adjustments To Reconcile Net Income		 2.54 2.34 -1.19 6.27 8.91 6.87 6.35 5.88 6.47 -0.39 3.63
Changes in Operating Assets and Liabilities, net		 -2.21 -2.77 2.04 5.29 0.43 0.94 -5.01 -6.32 4.56 3.13 -8.30
Net Cash From Investing Activities		 -0.65 -1.72 4.60 -1.78 -0.25 -0.17 -0.41 -0.33 -0.14 -0.14 -0.29
Net Cash From Continuing Investing Activities		 -0.65 -1.72 4.60 -1.78 0.15 -0.17 -0.41 -0.33 -0.14 -0.14 -0.29
Purchase of Property, Plant & Equipment		 -0.53 -1.50 -1.17 -1.32 -0.74 -0.12 -0.41 -0.33 -0.15 -0.16 -0.29
Other Investing Activities, net		 - - - 0.00 0.49 -0.02 - 0.00 0.01 0.02 0.00
Net Cash From Financing Activities		 4.34 0.75 49 -0.09 17 8.65 36 7.65 -0.09 5.37 6.92
Net Cash From Continuing Financing Activities		 4.34 0.75 49 -0.09 17 8.65 36 7.65 -0.09 5.37 6.92
Repayment of Debt		 -0.23 -5.40 -0.68 -0.22 -0.39 -0.32 -0.11 -0.09 -0.09 -0.05 -0.08
Repurchase of Common Equity		 - - - - -0.57 - - - - 0.00 -0.25
Other Financing Activities, net		 2.59 0.44 3.04 0.53 11 4.12 9.46 - 0.00 5.42 7.25
Cash Interest Paid		 0.43 0.26 0.06 0.04 0.03 0.01 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Niagen Bioscience

This table details how cash moves in and out of Niagen Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 0.55 0.24 0.32 4.51 12 11 4.86 3.82 0.50 1.76 -3.13
Net Cash From Operating Activities		 0.65 0.30 -0.26 3.50 8.58 7.88 1.25 3.69 0.68 -1.19 2.77
Net Cash From Continuing Operating Activities		 0.65 0.30 -0.26 3.50 8.58 7.88 1.25 3.69 0.68 -1.19 -0.55
Net Income / (Loss) Continuing Operations		 0.11 -0.49 -0.02 1.88 7.18 5.06 3.61 4.58 4.13 6.32 0.96
Consolidated Net Income / (Loss)		 0.11 -0.49 -0.02 1.88 7.18 5.06 3.61 4.58 4.13 6.32 0.96
Depreciation Expense		 0.18 0.18 0.17 0.16 0.15 0.16 0.16 0.16 0.14 0.12 0.12
Amortization Expense		 -0.48 0.04 0.20 0.20 -0.46 0.04 0.04 0.04 0.06 0.18 0.17
Non-Cash Adjustments To Reconcile Net Income		 1.75 1.21 1.22 0.75 -4.01 -0.06 1.75 1.92 0.02 -2.68 -1.82
Changes in Operating Assets and Liabilities, net		 -0.91 -0.64 -1.84 0.50 5.73 2.68 -4.30 -3.00 -3.67 -5.12 0.02
Net Cash From Investing Activities		 -0.02 -0.04 -0.01 -0.02 -0.07 -0.03 -0.14 -0.02 -0.10 5.25 -0.09
Net Cash From Continuing Investing Activities		 -0.02 -0.04 -0.01 -0.02 -0.07 -0.03 -0.14 -0.02 -0.10 5.25 -0.09
Other Investing Activities, net		 - - - 0.02 -0.16 0.00 - - - -0.49 -0.15
Net Cash From Financing Activities		 -0.08 -0.01 0.60 1.04 3.75 3.11 3.74 0.15 -0.08 -2.29 -2.49
Net Cash From Continuing Financing Activities		 -0.08 -0.01 0.60 1.04 3.75 3.11 3.74 0.15 -0.08 -2.29 -2.49
Repurchase of Common Equity		 - - - - - 0.00 - - - -2.35 -2.77
Other Financing Activities, net		 - 0.00 - 1.04 3.79 3.11 3.75 0.14 0.24 0.06 0.21

Annual Balance Sheets for Niagen Bioscience

This table presents Niagen Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/2/2016 12/31/2016 12/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 19 20 63 42 40 38 58 54 55 68 106
Total Current Assets		 17 16 57 37 34 32 49 47 50 64 97
Cash & Equivalents		 5.55 1.64 45 23 19 17 - 20 27 45 65
Accounts Receivable		 2.45 5.85 5.34 4.36 - 2.69 5.23 8.48 5.23 7.77 9.74
Inventories, net		 8.17 7.91 5.80 8.25 12 12 14 15 15 9.19 20
Prepaid Expenses		 0.37 0.31 0.66 0.58 1.00 1.15 1.86 2.97 2.45 2.48 1.31
Other Current Assets		 - - 0.00 0.73 2.18 - - - - 0.00 0.54
Plant, Property, & Equipment, net		 1.79 1.78 2.87 3.59 3.77 0.00 0.00 2.80 2.14 1.72 1.32
Total Noncurrent Assets		 0.41 2.24 2.67 2.11 2.96 6.14 8.94 4.69 3.29 2.46 8.28
Intangible Assets		 0.35 0.49 1.65 1.55 1.31 1.08 0.86 0.67 0.51 0.36 5.66
Other Noncurrent Operating Assets		 0.06 0.38 1.02 0.57 1.65 1.85 5.08 4.02 2.78 2.10 2.62
Total Liabilities & Shareholders' Equity		 19 20 63 42 40 38 58 54 55 68 106
Total Liabilities		 13 9.78 8.89 15 20 22 26 25 27 22 30
Total Current Liabilities		 9.59 8.87 8.09 14 15 16 18 18 21 18 20
Accounts Payable		 6.22 5.98 3.72 9.55 9.63 9.45 10 9.68 10 8.53 11
Accrued Expenses		 1.30 2.17 3.65 4.44 4.42 6.13 6.48 7.34 9.49 7.82 7.72
Current Deferred Revenue		 0.04 0.08 0.11 - - 0.28 - 0.16 0.20 0.61 0.40
Current Employee Benefit Liabilities		 - 0.00 0.10 - - - - - - - 0.00
Other Current Liabilities		 - - - 0.17 0.85 0.62 0.55 0.70 0.70 0.99 1.00
Total Noncurrent Liabilities		 3.89 0.91 0.80 0.61 4.74 5.46 8.50 7.52 5.89 4.24 9.95
Noncurrent Deferred Revenue		 0.10 0.38 0.49 0.48 3.87 4.44 4.35 3.96 3.31 2.58 2.67
Noncurrent Employee Benefit Liabilities		 - - - - - - - - - 0.00 5.47
Other Noncurrent Operating Liabilities		 - - - 0.14 0.87 1.00 4.15 3.56 2.58 1.66 1.82
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 5.27 9.97 54 27 20 16 32 29 28 46 77
Total Preferred & Common Equity		 5.27 9.97 54 27 20 16 32 29 28 46 77
Total Common Equity		 5.27 9.97 54 27 20 16 32 29 28 46 77
Common Stock		 48 55 110 117 142 158 201 214 219 228 241
Retained Earnings		 -42 -45 -57 -90 -122 -142 -169 -185 -190 -182 -165
Other Equity Adjustments		 - - - - 0.00 -0.00 -0.00 -0.00 -0.00 - -0.01

Quarterly Balance Sheets for Niagen Bioscience

This table presents Niagen Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 54 53 53 54 54 57 81 92 98 114 107
Total Current Assets		 47 46 47 49 49 52 76 87 94 105 98
Cash & Equivalents		 23 26 27 28 28 32 56 60 64 67 67
Accounts Receivable		 9.22 6.12 5.60 6.60 7.82 7.10 7.05 9.66 8.51 13 8.58
Inventories, net		 12 12 13 12 12 11 11 14 19 24 21
Prepaid Expenses		 2.30 1.89 2.18 2.31 2.09 2.10 2.37 2.14 2.03 1.49 1.83
Other Current Assets		 - - - - - - - - - 0.00 0.00
Plant, Property, & Equipment, net		 2.69 2.50 2.29 2.00 1.84 1.72 1.66 1.63 1.50 1.30 1.25
Total Noncurrent Assets		 4.51 4.29 4.01 3.10 2.89 2.67 3.46 3.21 3.02 7.91 7.56
Intangible Assets		 0.63 0.59 0.55 0.47 0.44 0.40 0.32 0.28 0.25 5.49 5.31
Other Noncurrent Operating Assets		 3.88 3.70 3.46 2.63 2.46 2.27 3.14 2.93 2.78 2.43 2.25
Total Liabilities & Shareholders' Equity		 54 53 53 54 54 57 81 92 98 114 107
Total Liabilities		 26 26 26 25 23 22 26 27 27 32 24
Total Current Liabilities		 18 19 19 19 18 18 21 22 23 23 15
Accounts Payable		 8.95 10 9.20 7.90 8.11 6.90 11 14 13 13 9.44
Accrued Expenses		 8.61 8.08 9.19 10 8.62 9.59 9.05 7.38 8.70 7.62 3.84
Current Deferred Revenue		 0.15 0.17 0.19 0.23 0.16 0.18 0.21 0.30 0.29 0.38 0.33
Current Employee Benefit Liabilities		 - - - - - - - - - 0.51 0.52
Other Current Liabilities		 0.71 0.79 0.86 0.86 0.99 1.02 0.95 0.96 0.98 1.03 0.92
Total Noncurrent Liabilities		 7.33 6.96 6.73 5.68 5.45 4.45 5.16 5.00 4.75 9.18 9.01
Noncurrent Deferred Revenue		 3.96 3.81 3.81 3.31 3.31 2.58 2.58 2.67 2.67 2.57 2.43
Noncurrent Employee Benefit Liabilities		 - - - - - - - - - 5.06 5.17
Other Noncurrent Operating Liabilities		 3.37 3.15 2.93 2.37 2.14 1.88 2.58 2.33 2.08 1.54 1.41
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 28 27 27 29 31 34 55 64 71 82 83
Total Preferred & Common Equity		 28 27 27 29 31 34 55 64 71 82 83
Total Common Equity		 28 27 27 29 31 34 55 64 71 82 83
Common Stock		 215 217 218 220 222 223 232 237 239 241 240
Retained Earnings		 -187 -190 -191 -191 -191 -189 -177 -173 -169 -158 -157
Other Equity Adjustments		 - - - -0.00 -0.00 -0.01 -0.01 -0.00 -0.01 -0.00 -0.00

Annual Metrics And Ratios for Niagen Bioscience

This table displays calculated financial ratios and metrics derived from Niagen Bioscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 1/2/2016 12/31/2016 12/30/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 79,806,139.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 79,806,139.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.22
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 16.79% 21.13% -2.14% 48.85% 46.69% 28.01% 13.82% 6.82% 15.99% 19.18% 29.95%
EBITDA Growth		 65.10% -43.22% -530.06% -106.85% 8.08% 38.41% -38.74% 34.20% 72.70% 286.83% 97.31%
EBIT Growth		 60.51% -40.61% -463.71% -102.95% 3.28% 38.24% -36.36% 31.19% 69.94% 237.99% 107.93%
NOPAT Growth		 60.51% -40.61% -463.71% -102.55% 5.64% 36.57% -36.36% 31.19% 69.94% 290.34% 108.50%
Net Income Growth		 48.57% -5.67% -288.57% -192.81% 3.51% 38.02% -36.15% 39.03% 70.15% 273.15% 103.30%
EPS Growth		 46.67% 0.00% -225.00% -134.62% 8.20% 41.07% -21.21% 40.00% 70.83% 257.14% 81.82%
Operating Cash Flow Growth		 18.19% -39.10% -233.86% -113.26% 2.24% 48.14% -127.95% 37.52% 147.14% 70.14% 11.52%
Free Cash Flow Firm Growth		 13.85% -15.13% -182.35% -48.39% -0.79% 36.72% -89.08% 21.79% 117.91% 125.01% -26.74%
Invested Capital Growth		 87.61% 46.76% 15.88% -49.03% -64.20% -115.49% 1,486.56% 134.64% -86.26% 26.79% 719.04%
Revenue Q/Q Growth		 -18.31% 6.54% 39.15% 5.12% 9.52% 4.14% 3.55% 4.70% 0.24% 8.65% 3.78%
EBITDA Q/Q Growth		 -1.91% -187.04% -60.80% 1.62% -4.72% 13.31% 2.89% 19.04% 10.16% 338.85% -16.08%
EBIT Q/Q Growth		 -2.45% -132.04% -57.39% 1.40% -4.78% 12.28% 2.75% 17.21% 18.56% 1,628.41% -16.78%
NOPAT Q/Q Growth		 -2.45% -132.04% -57.39% 1.60% -2.02% 12.28% 2.75% 17.21% 18.56% 1,568.88% -16.18%
Net Income Q/Q Growth		 -7.75% -32.61% -141.94% 1.78% -2.02% 12.15% 2.77% 19.11% 23.68% 475.76% -14.92%
EPS Q/Q Growth		 42.86% -33.33% -85.71% 4.69% 0.00% 13.16% 6.98% 14.29% 30.00% 1,000.00% -20.00%
Operating Cash Flow Q/Q Growth		 -40.43% 26.24% -67.71% -7.01% 18.13% 5.63% -25.87% 23.41% 15.91% 190.04% -36.92%
Free Cash Flow Firm Q/Q Growth		 -13.64% 22.23% -69.18% 0.13% 24.95% -14.53% -27.34% 16.65% 23.69% 823.65% -62.92%
Invested Capital Q/Q Growth		 1.82% -23.31% -13.01% -17.79% -82.56% -106.31% 48.77% 3.94% 111.40% -27.25% 83.92%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 42.13% 47.96% 49.42% 50.88% 55.67% 59.53% 61.51% 59.40% 60.76% 61.84% 64.28%
EBITDA Margin		 -9.70% -11.47% -73.87% -102.66% -64.33% -30.95% -37.73% -23.24% -5.47% 8.57% 13.02%
Operating Margin		 -11.55% -13.41% -77.25% -105.12% -67.62% -33.50% -40.14% -25.85% -6.70% 7.76% 12.58%
EBIT Margin		 -11.55% -13.41% -77.25% -105.32% -69.45% -33.50% -40.14% -25.85% -6.70% 7.76% 12.41%
Profit (Net Income) Margin		 -15.49% -13.52% -53.67% -105.57% -69.45% -33.62% -40.22% -22.96% -5.91% 8.58% 13.43%
Tax Burden Percent		 105.24% 82.45% 68.83% 100.00% 100.00% 100.00% 100.00% 88.81% 100.00% 96.56% 95.55%
Interest Burden Percent		 127.44% 122.25% 100.93% 100.24% 100.00% 100.36% 100.20% 99.98% 88.19% 114.61% 113.24%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.44% 4.45%
Return on Invested Capital (ROIC)		 -35.85% -31.32% -137.50% -343.68% -707.34% -2,014.17% -1,164.43% -222.16% -83.73% 581.67% 236.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 184.13% 47.79% -137.86% -313.76% -657.92% -1,980.21% -1,128.00% -207.77% -79.46% 578.64% 232.70%
Return on Net Nonoperating Assets (RNNOA)		 -23.92% -7.09% 101.83% 261.43% 572.34% 1,906.09% 1,051.75% 167.39% 66.44% -558.73% -207.70%
Return on Equity (ROE)		 -59.77% -38.40% -35.66% -82.25% -135.01% -108.09% -112.68% -54.77% -17.29% 22.94% 28.35%
Cash Return on Invested Capital (CROIC)		 -96.77% -69.22% -152.21% -278.72% -612.78% 0.00% -647.44% -302.63% 67.95% 558.04% 79.57%
Operating Return on Assets (OROA)		 -13.65% -15.09% -39.71% -63.34% -77.95% -50.52% -56.29% -33.29% -10.27% 12.54% 18.39%
Return on Assets (ROA)		 -18.31% -15.21% -27.59% -63.49% -77.95% -50.70% -56.40% -29.56% -9.06% 13.88% 19.90%
Return on Common Equity (ROCE)		 -59.77% -38.40% -35.66% -82.25% -135.01% -108.09% -112.68% -54.77% -17.29% 22.94% 28.35%
Return on Equity Simple (ROE_SIMPLE)		 -52.54% -29.36% -21.14% -122.58% -157.24% -121.32% -85.50% -57.69% -17.35% 18.55% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.45 -2.03 -11 -23 -22 -14 -19 -13 -3.92 7.46 16
NOPAT Margin		 -8.09% -9.39% -54.07% -73.58% -47.33% -23.45% -28.10% -18.10% -4.69% 7.49% 12.02%
Net Nonoperating Expense Percent (NNEP)		 -219.98% -79.11% 0.36% -29.91% -49.42% -33.97% -36.43% -14.39% -4.27% 3.03% 3.34%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -13.77% 16.18% 20.32%
Cost of Revenue to Revenue		 57.87% 52.04% 50.58% 49.12% 44.33% 40.47% 38.49% 40.60% 39.24% 38.16% 35.72%
SG&A Expenses to Revenue		 40.26% 42.53% 86.73% 86.23% 74.38% 51.92% 53.94% 39.26% 29.89% 18.45% 20.91%
R&D to Revenue		 4.99% 11.64% 18.90% 17.36% 9.55% 5.76% 5.68% 6.70% 5.93% 6.04% 4.89%
Operating Expenses to Revenue		 53.68% 61.37% 126.66% 155.99% 123.28% 93.03% 101.65% 85.25% 67.46% 54.08% 51.70%
Earnings before Interest and Taxes (EBIT)		 -2.07 -2.91 -16 -33 -32 -20 -27 -19 -5.60 7.73 16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.74 -2.49 -16 -32 -30 -18 -25 -17 -4.57 8.54 17
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 30.41 12.58 5.26 6.95 12.56 18.06 8.05 4.36 3.78 8.79 6.63
Price to Tangible Book Value (P/TBV)		 32.60 13.22 5.43 7.37 13.42 19.33 8.27 4.47 3.84 8.86 7.16
Price to Revenue (P/Rev)		 8.97 5.79 13.36 5.99 5.55 5.01 3.79 1.74 1.29 4.07 3.92
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47.39 29.20
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.11% 3.42%
Enterprise Value to Invested Capital (EV/IC)		 30.47 16.11 26.64 36.47 145.72 0.00 64.76 12.72 70.82 251.43 37.70
Enterprise Value to Revenue (EV/Rev)		 8.97 5.74 11.25 5.27 5.14 4.72 3.37 1.45 0.96 3.62 3.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 42.22 26.28
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 46.67 27.56
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48.33 28.47
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.26 29.78 32.79
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 25.18 50.38 84.45
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.05 0.06 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.72 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.13 -0.15 -0.74 -0.83 -0.87 -0.96 -0.93 -0.81 -0.84 -0.97 -0.89
Leverage Ratio		 3.26 2.52 1.29 1.30 1.73 2.13 2.00 1.85 1.91 1.65 1.42
Compound Leverage Factor		 4.16 3.09 1.30 1.30 1.73 2.14 2.00 1.85 1.68 1.89 1.61
Debt to Total Capital		 51.22% 5.67% 0.93% 0.00% 0.00% 0.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 16.17% 2.42% 0.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 35.05% 3.25% 0.57% 0.00% 0.00% 0.12% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 48.78% 94.33% 99.07% 100.00% 100.00% 99.88% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -3.19 -0.24 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.01 0.43 2.87 0.00 0.00 0.91 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -2.18 -0.14 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -3.83 -0.29 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.01 0.52 3.92 0.00 0.00 1.20 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -2.62 -0.17 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.02 5.52 18.28 3.34 2.60 3.27 2.05 -1.01 -0.60 9.87 10.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.73 1.77 7.07 2.53 2.23 1.96 2.78 2.61 2.40 3.57 4.86
Quick Ratio		 0.83 0.85 6.27 1.87 1.25 1.18 0.30 1.62 1.58 2.92 3.74
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.90 -4.49 -13 -19 -19 -12 -23 -18 3.18 7.16 5.24
Operating Cash Flow to CapEx		 -401.94% -195.13% 0.00% -1,582.74% -2,750.87% -8,548.39% -5,907.82% -4,520.36% 4,808.78% 0.00% 4,624.66%
Free Cash Flow to Firm to Interest Expense		 -6.89 -6.95 -82.95 -238.37 0.00 -169.18 -412.95 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -3.72 -4.54 -64.08 -264.66 0.00 -149.30 -439.33 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -4.65 -6.87 -32.80 -281.38 0.00 -151.04 -446.76 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.18 1.13 0.51 0.60 1.12 1.51 1.40 1.29 1.53 1.62 1.48
Accounts Receivable Turnover		 8.21 5.22 3.79 6.51 0.00 0.00 17.03 10.51 12.19 15.32 14.78
Inventory Turnover		 1.74 1.40 1.56 2.21 2.07 2.07 2.05 2.07 2.25 3.21 3.12
Fixed Asset Turnover		 11.72 12.15 9.12 9.77 12.60 0.00 0.00 0.00 33.86 51.66 85.09
Accounts Payable Turnover		 2.14 1.85 2.21 2.34 2.14 2.52 2.61 2.91 3.29 4.05 4.79
Days Sales Outstanding (DSO)		 44.46 69.94 96.32 56.08 0.00 0.00 21.43 34.72 29.95 23.82 24.69
Days Inventory Outstanding (DIO)		 209.97 260.40 233.29 165.35 175.94 176.68 177.75 176.42 162.53 113.87 116.90
Days Payable Outstanding (DPO)		 170.60 197.52 165.03 156.19 170.51 145.12 139.68 125.41 110.82 90.06 76.27
Cash Conversion Cycle (CCC)		 83.83 132.82 164.59 65.24 5.42 31.56 59.51 85.73 81.66 47.63 65.32
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5.26 7.72 8.95 4.56 1.63 -0.25 3.51 8.23 1.13 1.43 12
Invested Capital Turnover		 4.43 3.34 2.54 4.67 14.94 85.88 41.44 12.28 17.85 77.66 19.64
Increase / (Decrease) in Invested Capital		 2.46 2.46 1.23 -4.39 -2.93 -1.89 3.76 4.72 -7.10 0.30 10
Enterprise Value (EV)		 160 124 238 166 238 280 227 105 80 361 443
Market Capitalization		 160 125 283 189 257 297 255 125 107 405 508
Book Value per Share		 $0.05 $0.26 $1.12 $0.49 $0.34 $0.27 $0.46 $0.39 $0.38 $0.60 $0.96
Tangible Book Value per Share		 $0.05 $0.25 $1.08 $0.47 $0.32 $0.25 $0.45 $0.38 $0.37 $0.60 $0.89
Total Capital		 11 11 54 27 20 16 32 29 28 46 77
Total Debt		 5.54 0.60 0.51 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 3.79 0.34 0.31 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.01 -1.06 -45 -23 -19 -17 -28 -20 -27 -45 -65
Capital Expenditures (CapEx)		 0.53 1.50 -4.79 1.32 0.74 0.12 0.41 0.33 0.15 0.00 0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.16 5.48 3.90 -0.52 -0.36 -0.95 3.07 8.26 1.59 1.49 12
Debt-free Net Working Capital (DFNWC)		 8.71 7.12 49 22 18 16 31 29 29 46 77
Net Working Capital (NWC)		 6.96 6.87 49 22 18 16 31 29 29 46 77
Net Nonoperating Expense (NNE)		 1.32 0.89 -0.09 10 10 6.03 8.18 3.50 1.02 -1.09 -1.83
Net Nonoperating Obligations (NNO)		 -0.01 -2.25 -45 -23 -19 -17 -28 -20 -27 -45 -65
Total Depreciation and Amortization (D&A)		 0.33 0.42 0.72 0.84 2.37 1.51 1.63 1.88 1.03 0.81 0.79
Debt-free, Cash-free Net Working Capital to Revenue		 17.67% 25.30% 18.38% -1.65% -0.77% -1.61% 4.56% 11.46% 1.90% 1.50% 9.35%
Debt-free Net Working Capital to Revenue		 48.70% 32.88% 232.47% 70.01% 39.87% 26.57% 46.39% 39.83% 34.60% 46.34% 59.41%
Net Working Capital to Revenue		 38.92% 31.70% 231.55% 70.01% 39.87% 26.57% 46.39% 39.83% 34.60% 46.34% 59.41%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.03) ($0.08) ($0.26) ($0.61) ($0.56) ($0.33) ($0.40) ($0.24) ($0.07) $0.11 $0.22
Adjusted Weighted Average Basic Shares Outstanding		 109.53M 37.91M 54.84M 55.29M 59.79M 66.74M 67.19M 69.73M 74.99M 75.93M 79.18M
Adjusted Diluted Earnings per Share		 ($0.03) ($0.08) ($0.26) ($0.61) ($0.56) ($0.33) ($0.40) ($0.24) ($0.07) $0.11 $0.20
Adjusted Weighted Average Diluted Shares Outstanding		 109.53M 37.91M 54.84M 55.29M 59.79M 66.74M 67.19M 69.73M 74.99M 78.13M 85.44M
Adjusted Basic & Diluted Earnings per Share		 ($0.03) ($0.08) ($0.26) ($0.61) ($0.56) ($0.33) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 107.63M 37.29M 44.60M 55.01M 57.06M 61.07M 68.31M 74.84M 75.31M 77.75M 80.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.45 -2.03 -11 -23 -22 -14 -19 -13 -3.92 7.46 16
Normalized NOPAT Margin		 -8.09% -9.39% -54.07% -73.58% -47.33% -23.45% -28.10% -18.10% -4.69% 7.49% 12.02%
Pre Tax Income Margin		 -14.72% -16.39% -77.97% -105.57% -69.45% -33.62% -40.22% -25.85% -5.91% 8.89% 14.06%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3.64 -4.49 -107.04 -420.72 0.00 -279.63 -492.24 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -2.55 -3.15 -74.93 -293.93 0.00 -195.74 -344.57 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -4.57 -6.82 -75.76 -437.44 0.00 -281.38 -499.67 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -3.48 -5.47 -43.65 -310.65 0.00 -197.49 -352.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -1.76% 0.00% 0.00% 0.00% 0.00% 0.00% 1.44%

Quarterly Metrics And Ratios for Niagen Bioscience

This table displays calculated financial ratios and metrics derived from Niagen Bioscience's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - 78,769,662.00 79,752,957.00 79,806,139.00 80,080,488.00 79,644,327.00
DEI Adjusted Shares Outstanding		 - - - - - - 78,769,662.00 79,752,957.00 79,806,139.00 80,080,488.00 79,644,327.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - 0.05 0.06 0.05 0.08 0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.95% -1.79% 11.89% 31.21% 37.41% 37.59% 36.84% 32.86% 16.19% 3.26% -4.28%
EBITDA Growth		 52.28% 66.30% 106.09% 381.55% 1,540.47% 1,064.47% 7,000.00% 145.62% -41.30% 33.90% -70.78%
EBIT Growth		 88.37% 62.86% 88.95% 239.67% 4,332.74% 752.80% 1,344.14% 164.42% -42.54% 33.28% -78.12%
NOPAT Growth		 83.38% 62.86% 88.95% 299.53% 4,332.74% 1,002.63% 1,816.47% 152.19% -44.05% -67.99% -79.50%
Net Income Growth		 108.04% 74.13% 99.32% 295.83% 6,197.37% 1,129.07% 24,160.00% 143.77% -42.44% 24.79% -73.32%
EPS Growth		 0.00% 66.67% 100.00% 300.00% 0.00% 700.00% 0.00% 150.00% -50.00% 16.67% -75.00%
Operating Cash Flow Growth		 297.87% -89.43% -108.05% 782.58% 1,222.50% 2,572.20% 573.48% 5.64% -92.09% -115.15% 121.76%
Free Cash Flow Firm Growth		 220.90% 502.69% -214.16% -97.48% -1.79% 110.72% 196.46% -325.85% -199.64% -332.22% -622.71%
Invested Capital Growth		 -86.26% -71.58% 280.78% 268.41% 26.79% -119.55% 31.34% 224.00% 719.04% 5,923.25% 324.29%
Revenue Q/Q Growth		 8.73% 4.52% 2.65% 12.49% 13.86% 4.66% 2.09% 9.22% -0.43% -6.99% -5.37%
EBITDA Q/Q Growth		 32.48% -9.11% 133.43% 1,626.32% 245.48% -26.95% -31.93% 31.06% -3.30% 55.22% -85.15%
EBIT Q/Q Growth		 85.35% -335.12% 64.98% 725.78% 343.88% -32.89% -33.26% 33.00% -3.54% 55.65% -89.04%
NOPAT Q/Q Growth		 79.08% -204.58% 64.98% 993.97% 343.88% -35.05% -33.40% 31.35% -5.54% -61.26% -57.35%
Net Income Q/Q Growth		 111.89% -531.58% 96.95% 12,620.00% 282.27% -29.47% -28.72% 26.85% -9.74% 52.90% -84.76%
EPS Q/Q Growth		 0.00% 0.00% 100.00% 0.00% 400.00% -40.00% -33.33% 25.00% 0.00% 40.00% -85.71%
Operating Cash Flow Q/Q Growth		 63.89% -54.55% -189.49% 1,423.86% 145.58% -8.16% -84.14% 195.36% -81.61% -275.85% 332.16%
Free Cash Flow Firm Q/Q Growth		 5.33% -57.04% -176.16% 107.32% 4,001.20% -7.82% -65.14% -117.14% -1,632.31% -124.39% 21.53%
Invested Capital Q/Q Growth		 111.40% 22.55% 104.40% -30.43% -27.25% -118.90% 1,473.06% 71.62% 83.92% 34.36% 0.04%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 61.04% 60.74% 60.22% 63.49% 62.48% 63.42% 65.00% 64.52% 64.14% 63.47% 64.84%
EBITDA Margin		 -2.23% -2.32% 0.50% 7.69% 23.34% 16.30% 10.87% 13.04% 12.66% 21.13% 3.32%
Operating Margin		 -0.79% -3.30% -1.13% 6.26% 24.42% 15.66% 10.24% 12.46% 12.07% 5.01% 2.35%
EBIT Margin		 -0.79% -3.30% -1.13% 6.26% 24.42% 15.66% 10.24% 12.46% 12.07% 20.21% 2.34%
Profit (Net Income) Margin		 0.54% -2.22% -0.07% 7.34% 24.65% 16.61% 11.60% 13.47% 12.21% 20.07% 3.23%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 95.92% 96.79% 96.57% 95.38% 93.40% 93.81% 90.08%
Interest Burden Percent		 -67.86% 67.31% 5.86% 117.23% 105.25% 109.62% 117.33% 113.31% 108.27% 105.90% 153.37%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 3.21% 3.43% 4.63% 6.60% 6.19% 9.92%
Return on Invested Capital (ROIC)		 -14.15% -61.36% -37.71% 458.17% 1,896.07% 2,933.40% 350.82% 354.79% 221.51% 78.99% 28.02%
ROIC Less NNEP Spread (ROIC-NNEP)		 -15.33% -61.43% -38.32% 457.24% 1,895.88% 2,932.33% 349.62% 353.67% 220.93% 71.07% 27.49%
Return on Net Nonoperating Assets (RNNOA)		 12.82% 54.68% 35.95% -438.66% -1,830.65% -2,893.55% -325.48% -325.54% -197.19% -63.06% -23.84%
Return on Equity (ROE)		 -1.33% -6.68% -1.76% 19.51% 65.42% 39.85% 25.35% 29.25% 24.32% 15.93% 4.18%
Cash Return on Invested Capital (CROIC)		 67.95% 13.94% -206.90% -78.93% 558.04% 0.00% 464.92% 338.43% 79.57% -23.27% -21.68%
Operating Return on Assets (OROA)		 -1.22% -5.09% -1.80% 10.44% 39.46% 24.95% 16.36% 20.10% 17.89% 26.94% 3.05%
Return on Assets (ROA)		 0.82% -3.43% -0.11% 12.24% 39.84% 26.48% 18.53% 21.72% 18.09% 26.76% 4.21%
Return on Common Equity (ROCE)		 -1.33% -6.68% -1.76% 19.51% 65.42% 39.85% 25.35% 29.25% 24.32% 15.93% 4.18%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -12.19% -4.40% 4.32% 0.00% 25.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.17 -0.51 -0.18 1.60 7.11 4.62 3.08 4.04 3.82 1.48 0.63
NOPAT Margin		 -0.79% -2.31% -0.79% 6.26% 24.42% 15.15% 9.89% 11.89% 11.28% 4.70% 2.12%
Net Nonoperating Expense Percent (NNEP)		 1.18% 0.08% 0.60% 0.93% 0.19% 1.07% 1.21% 1.11% 0.58% 7.92% 0.52%
Return On Investment Capital (ROIC_SIMPLE)		 -0.59% -1.77% - - 15.43% 8.35% 4.79% 5.72% 4.99% 1.80% 0.76%
Cost of Revenue to Revenue		 38.96% 39.26% 39.78% 36.51% 37.52% 36.58% 35.00% 35.48% 35.86% 36.53% 35.16%
SG&A Expenses to Revenue		 25.60% 24.16% 24.91% 24.64% 3.62% 17.01% 23.35% 20.98% 22.10% 23.02% 23.40%
R&D to Revenue		 5.47% 9.46% 5.79% 5.04% 4.52% 4.13% 5.04% 5.28% 5.05% 4.71% 5.08%
Operating Expenses to Revenue		 61.83% 64.04% 61.34% 57.22% 38.06% 47.76% 54.76% 52.06% 52.06% 58.46% 62.49%
Earnings before Interest and Taxes (EBIT)		 -0.17 -0.73 -0.26 1.60 7.11 4.77 3.19 4.24 4.09 6.36 0.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.47 -0.52 0.11 1.97 6.80 4.97 3.38 4.43 4.29 6.65 0.99
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.78 9.05 6.71 8.06 8.79 9.69 17.68 10.53 6.63 4.29 3.08
Price to Tangible Book Value (P/TBV)		 3.84 9.20 6.81 8.16 8.86 9.75 17.76 10.57 7.16 4.60 3.29
Price to Revenue (P/Rev)		 1.29 3.15 2.41 3.02 4.07 4.97 9.76 5.97 3.92 2.71 1.97
Price to Earnings (P/E)		 0.00 0.00 0.00 186.64 47.39 38.03 64.02 36.42 29.20 18.95 15.89
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.54% 2.11% 2.63% 1.56% 2.75% 3.42% 5.28% 6.29%
Enterprise Value to Invested Capital (EV/IC)		 70.82 169.20 62.95 124.18 251.43 0.00 288.79 106.45 37.70 18.16 11.87
Enterprise Value to Revenue (EV/Rev)		 0.96 2.82 2.08 2.67 3.62 4.46 9.24 5.45 3.42 2.20 1.45
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 125.77 42.22 34.29 61.57 33.86 26.28 15.46 11.61
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 547.56 46.67 36.35 64.46 35.22 27.56 16.24 12.35
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 547.56 48.33 37.57 66.65 36.63 28.47 23.15 18.82
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.26 50.76 165.74 58.62 29.78 24.41 50.66 31.75 32.79 64.74 31.49
Enterprise Value to Free Cash Flow (EV/FCFF)		 25.18 537.13 0.00 0.00 50.38 33.26 70.53 48.07 84.45 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.84 -0.89 -0.94 -0.96 -0.97 -0.99 -0.93 -0.92 -0.89 -0.89 -0.87
Leverage Ratio		 1.91 1.89 1.85 1.78 1.65 1.61 1.53 1.47 1.42 1.42 1.35
Compound Leverage Factor		 -1.30 1.27 0.11 2.09 1.74 1.76 1.80 1.67 1.54 1.51 2.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.28 3.46 2.63 5.27 9.84 11.68 24.50 16.13 10.24 6.87 6.43
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.40 2.52 2.76 2.95 3.57 3.66 3.88 4.12 4.86 4.61 6.50
Quick Ratio		 1.58 1.76 2.00 2.23 2.92 3.01 3.14 3.21 3.74 3.49 5.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 6.93 2.98 -2.27 0.17 6.81 6.28 2.19 -0.37 -6.49 -15 -11
Operating Cash Flow to CapEx		 3,090.48% 719.51% -2,200.00% 8,524.39% 0.00% 24,634.38% 925.93% 15,383.33% 672.28% -1,957.38% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.53 1.54 1.60 1.67 1.62 1.59 1.60 1.61 1.48 1.33 1.30
Accounts Receivable Turnover		 12.19 10.51 12.28 14.44 15.32 15.81 13.31 15.99 14.78 12.96 14.16
Inventory Turnover		 2.25 2.66 2.86 3.05 3.21 3.42 3.27 3.07 3.12 2.65 2.63
Fixed Asset Turnover		 33.86 35.47 39.42 45.71 51.66 59.06 66.98 77.53 85.09 88.33 89.67
Accounts Payable Turnover		 3.29 3.85 3.70 4.39 4.05 4.37 3.88 4.58 4.79 3.90 3.99
Days Sales Outstanding (DSO)		 29.95 34.73 29.72 25.28 23.82 23.09 27.42 22.83 24.69 28.16 25.78
Days Inventory Outstanding (DIO)		 162.53 137.25 127.83 119.64 113.87 106.80 111.79 118.90 116.90 137.91 138.55
Days Payable Outstanding (DPO)		 110.82 94.77 98.72 83.14 90.06 83.58 93.97 79.62 76.27 93.67 91.40
Cash Conversion Cycle (CCC)		 81.66 77.21 58.83 61.77 47.63 46.32 45.24 62.11 65.32 72.40 72.94
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.13 1.39 2.83 1.97 1.43 -0.27 3.72 6.39 12 16 16
Invested Capital Turnover		 17.85 26.56 47.85 73.16 77.66 193.59 35.49 29.85 19.64 16.82 13.23
Increase / (Decrease) in Invested Capital		 -7.10 -3.49 2.09 1.44 0.30 -1.66 0.89 4.42 10 16 12
Enterprise Value (EV)		 80 235 178 245 361 481 1,075 680 443 287 187
Market Capitalization		 107 262 206 277 405 536 1,135 744 508 353 254
Book Value per Share		 $0.38 $0.38 $0.41 $0.45 $0.60 $0.71 $0.82 $0.89 $0.96 $1.03 $1.04
Tangible Book Value per Share		 $0.37 $0.38 $0.40 $0.45 $0.60 $0.71 $0.81 $0.88 $0.89 $0.96 $0.97
Total Capital		 28 29 31 34 46 55 64 71 77 82 83
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -27 -28 -28 -32 -45 -56 -60 -64 -65 -67 -67
Capital Expenditures (CapEx)		 0.02 0.04 0.01 0.04 0.00 0.03 0.14 0.02 0.10 0.06 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.59 1.96 3.55 2.04 1.49 -0.24 3.88 6.61 12 16 16
Debt-free Net Working Capital (DFNWC)		 29 30 31 34 46 55 64 71 77 82 83
Net Working Capital (NWC)		 29 30 31 34 46 55 64 71 77 82 83
Net Nonoperating Expense (NNE)		 -0.28 -0.02 -0.16 -0.28 -0.07 -0.44 -0.53 -0.54 -0.32 -4.84 -0.33
Net Nonoperating Obligations (NNO)		 -27 -28 -28 -32 -45 -56 -60 -64 -65 -67 -67
Total Depreciation and Amortization (D&A)		 -0.30 0.22 0.37 0.37 -0.31 0.20 0.20 0.20 0.20 0.29 0.29
Debt-free, Cash-free Net Working Capital to Revenue		 1.90% 2.36% 4.15% 2.22% 1.50% -0.22% 3.33% 5.30% 9.35% 12.08% 12.39%
Debt-free Net Working Capital to Revenue		 34.60% 35.50% 36.73% 37.56% 46.34% 51.31% 55.33% 56.86% 59.41% 63.10% 64.09%
Net Working Capital to Revenue		 34.60% 35.50% 36.73% 37.56% 46.34% 51.31% 55.33% 56.86% 59.41% 63.10% 64.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.01) $0.00 $0.02 $0.10 $0.07 $0.05 $0.06 $0.04 $0.08 $0.01
Adjusted Weighted Average Basic Shares Outstanding		 74.99M 75.23M 75.56M 75.97M 75.93M 77.81M 79.25M 79.78M 79.18M 79.92M 79.32M
Adjusted Diluted Earnings per Share		 $0.00 ($0.01) $0.00 $0.02 $0.10 $0.06 $0.04 $0.05 $0.05 $0.07 $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 74.99M 75.23M 75.56M 77.77M 78.13M 83.23M 86.24M 86.62M 85.44M 84.57M 82.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 75.31M 75.54M 75.93M 76.38M 77.75M 78.77M 79.75M 79.81M 80.08M 79.64M 79.13M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.12 -0.51 -0.18 1.12 4.98 4.62 3.08 4.04 3.82 1.48 0.63
Normalized NOPAT Margin		 -0.55% -2.31% -0.79% 4.38% 17.09% 15.15% 9.89% 11.89% 11.28% 4.70% 2.12%
Pre Tax Income Margin		 0.54% -2.22% -0.07% 7.34% 25.70% 17.16% 12.01% 14.12% 13.07% 21.40% 3.59%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.44% 13.98% 33.59%

Financials Breakdown Chart

Key Financial Trends

Niagen Bioscience (NASDAQ:NAGE) has shown a meaningful improvement in operating performance over the supplied period, although the latest quarter points to slower growth and weaker cash conversion. The financial data identifies the reporting company as ChromaDex Corp., so investors should confirm the issuer and ticker before relying on these figures.

Revenue increased from $17.1 million in Q3 2022 to $29.8 million in Q2 2026, with revenue reaching a recent high of $34.0 million in Q3 2025. However, Q2 2026 revenue declined 4.3% year over year and 5.4% from Q1 2026. Gross margin remained relatively stable at approximately 64.9% in Q2 2026, compared with 65.0% in the prior-year quarter.

Profitability has improved substantially. The company reported operating income in each quarter from Q3 2024 through Q2 2026, compared with operating losses in several earlier periods. Q2 2026 operating income was $700,000, while net income was $963,000, or $0.01 per diluted share. The quarter was less profitable than Q1 2026, which included $4.8 million of other income.

The balance sheet remains a major source of financial flexibility. Cash and equivalents totaled $66.7 million at June 30, 2026, while total liabilities were $24.1 million. The company had approximately $6.50 of current assets for every dollar of current liabilities. Accounts receivable and inventory also declined from the prior quarter, potentially reducing working-capital pressure.

  • Revenue has grown over the longer term: Quarterly revenue rose from $17.1 million in Q3 2022 to $29.8 million in Q2 2026, despite the latest year-over-year decline.
  • Operating profitability has improved: Operating income was $700,000 in Q2 2026 versus an operating loss of $256,000 in Q2 2024 and a loss of $2.3 million in Q2 2023.
  • Gross margins remain resilient: The Q2 2026 gross margin was approximately 64.9%, broadly consistent with the 63% to 65% range reported in recent quarters.
  • Liquidity is strong: Cash of $66.7 million substantially exceeded current liabilities of $15.1 million, providing a sizable cushion for operations and investment.
  • Working-capital balances improved sequentially: Accounts receivable fell from $13.1 million in Q1 2026 to $8.6 million, while inventory declined from $24.0 million to $20.6 million.
  • Share repurchases are reducing the share count modestly: The company repurchased $2.8 million of common stock in Q2 2026 and $2.4 million in Q1 2026; basic weighted-average shares declined from 79.9 million to 79.3 million sequentially.
  • Cash flow is uneven: Reported operating cash flow was $2.8 million in Q2 2026, but cash flow from continuing operating activities was negative $551,000. This difference makes the underlying quality and sustainability of cash generation worth monitoring.
  • Equity has strengthened over the longer term: Total equity increased from $21.0 million in Q3 2022 to $82.5 million in Q2 2026, although this improvement has occurred alongside substantial stock issuance and other equity activity.
  • Recent revenue momentum has slowed: Q2 2026 revenue fell 4.3% year over year and 5.4% sequentially, reversing the stronger growth reported in Q3 and Q4 2025.
  • Marketing spending is rising faster than sales: Marketing expense increased to $10.1 million in Q2 2026 from $8.2 million in the prior-year quarter, contributing to a decline in operating margin despite stable gross margins.

Overall, the statements show a company that has moved from recurring operating losses to modest operating profitability and maintains a strong cash position. The key risks for investors are whether revenue growth resumes, whether marketing spending produces sufficient sales, and whether positive reported cash flow can be sustained without relying on non-operating items or balance-sheet changes.

10/15/26 10:59 AM ETAI Generated. May Contain Errors.

Niagen Bioscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Niagen Bioscience's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Niagen Bioscience's net income appears to be on an upward trend, with a most recent value of $17.38 million in 2025, compared with -$2.77 million in 2015. The previous period was $8.55 million in 2024. Check out Niagen Bioscience's forecast to explore projected trends and price targets.

Niagen Bioscience's total operating income in 2025 was $16.28 million, based on the following breakdown:
  • Total Gross Profit: $83.19 million
  • Total Operating Expenses: $66.91 million

Over the last 10 years, Niagen Bioscience's total revenue changed from $17.88 million in 2015 to $129.42 million in 2025, a change of 623.6%.

In the past 13 quarters, Niagen Bioscience's cash and equivalents has ranged from $23.14 million in Q1 2023 to $66.74 million in Q2 2026, and is currently $66.74 million as of their latest financial filing in Q2 2026.

Niagen Bioscience had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2015.

Over the last 10 years, Niagen Bioscience's book value per share changed from 0.05 in 2015 to 0.96 in 2025, a change of 1,885.5%.


Related Companies

Financial statements for NASDAQ:NAGE last updated on 8/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel